Drug intelligence / Profile preview

methylprednisolone + prednisone

Development stage
Unknown
Lead developer
Pfizer
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral, Intravenous, Intramuscular
01

Overview

Methylprednisolone and prednisone are synthetic glucocorticoids belonging to the corticosteroid class. Both drugs act as agonists of the glucocorticoid receptor, inhibiting pro-inflammatory signals and promoting anti-inflammatory effects. They are used to treat a wide range of inflammatory and autoimmune conditions, including arthritis, asthma, allergic reactions, lupus, psoriasis, ulcerative colitis, glandular disorders, skin diseases, blood disorders, kidney disease, eye conditions, thyroid disorders (such as colitis), severe allergies and certain types of cancer[1][2][3][4][5][6]. Methylprednisolone is available in oral tablet form as well as injectable preparations for rapid or localized relief; it is slightly more potent than prednisone (4 mg methylprednisolone ≈ 5 mg prednisone)[3]. Prednisone is commonly prescribed in oral tablet or solution form and is metabolized in the liver to its active form prednisolone[6]. Both drugs suppress immune function by altering gene expression through binding to the glucocorticoid receptor; this leads to decreased vasodilation and capillary permeability along with reduced leukocyte migration[6]. High doses can cause immunosuppression by interfering with cellular energy metabolism[8].

Brand names
Depo-Medrol
Other names
none
02

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on methylprednisolone + prednisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on methylprednisolone + prednisone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call